echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > A new wave of drug price cuts in India affects more than 100 kinds of diabetes and cardiovascular drugs

    A new wave of drug price cuts in India affects more than 100 kinds of diabetes and cardiovascular drugs

    • Last Update: 2014-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: China Journal of new drugs 2014-07-16 India announced in May last year that it set a price ceiling for 652 drugs (348 are basic drugs), among which the price of some anti-cancer and anti HIV drugs will be reduced by as much as 80%, and the new price standard will be implemented from July 1, 2013 At that time, analysts thought that India's move would significantly reduce the profits of foreign drug manufacturers, especially GSK and Sanofi Although Cipla and Cadila, the local drug companies, would receive some impact, sun pharma and lupin, the generic drug manufacturers, would hardly be affected As a result of this round of price cuts, the National Pharmaceutical Pricing Authority (NPPA) announced that it would start to reduce the pricing of more than 100 kinds of diabetes and cardiovascular drugs from July 11, 2014 "If the maximum retail price of a drug is 25% higher than the average price of a drug of the same category, or the price of a new drug is higher than that of the drug of the same category, NPPA has the right to adjust its price," NPPA said in the announcement If the price difference between the original research drug and the similar generic drug is too large, it usually indicates that the drug will face a major failure in the Indian market " The drugs targeted in India this time mainly include some diabetes drugs (such as gliclazide, glimepiride, voglibose), antihypertensive drugs (amlodipine, telmisartan) and lipid-lowering drugs (rosuvastatin) NPPA expects to reduce the price of these drugs by about 35% to achieve the goal of reducing the average price of similar drugs by 12% Analysts at Nomura Securities in Japan believe that Sanofi, Abbott and Ranbaxy are most affected by this round of price cuts Although the impact of current price cuts is limited, NPPA's new measures mean that India opens a new round of drug price cuts, which undoubtedly increases the risk of drug price cuts in the future Dr shailesh ayyangar, President of Sanofi India, said the price cut in India was shocking and disappointing Dilip Shah, Secretary General of the Indian Pharmaceutical alliance, commented on the news: Napa The goal of formulating policies and adjusting drug prices is to expand the coverage of the basic drug catalog While ensuring that patients with strong ability to pay can buy the original research drug, ensuring that patients with weak ability to pay can buy generic drugs smoothly The new round of price reduction undoubtedly shows the strong control ability of the Indian government on drug prices ".
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.